ClinicalTrials.gg
RecruitingNCT06817148BELIEVE-ITUpdated Feb 10, 2025

Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial

An interventional study of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in Aortic Valve Stenosis and Bicuspid Aortic Valve, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Aortic Valve Stenosis with a site in United States — 43 open to participants now, 67 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.

Planned enrollment
53rd of 125
250 · median 172
Started
2025
with 11 others
No phase
102 of 189
21 open now
Primary completion
2028-02
later than 43 of 66 live
Registered
173rd of 189
by date

Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 53rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 12 that started in 2025, is one of 102 with no phase, reaches primary completion later than 43 of the 66 other live ones, and was the 173rd registered.

Aortic Valve Stenosis

1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Aortic Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review.

The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) versus Surgical Aortic Valve Replacement (SAVR) for treating patients with severe aortic stenosis (AS) who have a congenital bicuspid aortic valve (BAV) anatomy. Patients with BAV anatomy have been under-represented in previous trials and this study might provide important information to help guide future treatment options.

The study patients will be followed with standard of care procedures for 10 years.

03

Conditions studied

  • Aortic Valve Stenosis
  • Bicuspid Aortic Valve

Keywords

  • TAVR
  • BAV
  • SAVR
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged > 50 years of age
  • Site-determined severe AS deemed necessary for treatment with SAVR or TAVR
  • Gated contrast CT available and suitable for core laboratory analysis
  • BAV anatomy confirmed by CT core laboratory analysis

Exclusion criteria

Exclusion Criteria:

  • Recent cardiovascular intervention within the prior 30 days.
  • Presence of an existing TAVR or SAVR device
  • Pregnancy or lactation
  • Extreme or prohibitive TAVR or SAVR risk, determined by site or committee Active enrollment in another study
  • Disproportionate TAVR vs SAVR risk, as determined by treating site or committee
  • Associated aortopathy (AA≥ 45 mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA\<45 mm but site plan for surgery of the aorta in the event of randomization to surgery
  • Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)
  • In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    transcatheter aortic valve replacement (TAVR)

    50% of patients will be treated with standard TAVR procedure and followed up for 10 years

    Procedure: transcatheter aortic valve replacement (TAVR)

  • Active comparator
    surgical aortic valve replacement (SAVR)

    50% of patients will be treated with standard SAVR procedure and followed up for 10 years

    Procedure: surgical aortic valve replacement (SAVR)

Interventions

  • Proceduretranscatheter aortic valve replacement (TAVR)

    percutaneous transcatheter aortic valve replacement

  • Proceduresurgical aortic valve replacement (SAVR)

    surgical aortic valve replacement

06

What researchers measure

Primary outcomes

  1. 1 year hierarchical composite outcome of death, disabling stroke, non-disabling stroke, valve reintervention, rehospitalization, unfavorable KCCQ (VARC 3)

    The primary endpoint will be analyzed by the Win ratio method14. That is, every patient in the TAVR group will be compared with every patient in the SAVR group to determine which pair has won. A win higher up in the hierarchy takes priority, so KCCQ gets used only for those pairs that were tied on the first 5 event components. Then KCCQ win is declared if the time-averaged change in KCCQ differs by 5 points or more. The win ratio= total wins on TAVR divided by total wins on SAVR, for which a 95% CI and p value is calculated.

    Time frame: 1 year

Secondary outcomes

  1. Technical success at time of exit from OR/cath lab

    defined as meeting of the following: * Alive * Successful access, delivery and retrieval of the device delivery system * Deployment and correct positioning (including repositioning /recapture if needed) of the single intended valve * No additional unplanned or emergency surgery or re-intervention prior to leaving OR/Cath lab related to the device or access procedure (includes need for return to bypass post initial wean

    Time frame: exit from procedure (OR or cath lab)

  2. Device success

    Defined as meeting all of the following: * Alive and stroke-free * Original intended device in place * No additional surgical or interventional procedures related to access or the device since completion of the original procedure (i.e., exit from the cath lab/OR) * Intended performance of the device: 1. Structural performance: No migration, embolization, detachment, fracture, or thrombosis 2. Hemodynamic performance: Mean gradient \< 20mmHg, AVA \>1cm2, jet velocity \< 3.0 m/s 3. Absence of the following para-device complications (PVL \> mild, erosion, hemolysis, or endocarditis)

    Time frame: 30 days

  3. Procedural success

    Defined as meeting all of the following: 1. Life-threatening bleed (BARC 3b or greater) 2. Major vascular or cardiac structural complications requiring unplanned reintervention or surgery 3. Stage 2 or 3 AKI (includes new dialysis) 4. MI or need for PCI/CABG 5. Severe heart failure or hypotension requiring IV inotrope \>12 hours, ultrafiltration or mechanical circulatory support 6. Prolonged intubation \> 48 hours 7. Need for a permanent pacemaker implant or continuous, new onset atrial fibrillation

    Time frame: 30 Days

  4. Patient success

    Defined as meeting all of the following: * Device success * No re-hospitalizations or re-interventions for the underlying condition (e.g., Aortic stenosis and Heart Failure) * Return to prior living arrangement (or equivalent) * Improvement in symptoms defined as increase in NYHA Class \> 1 compared to Baseline * Improvement in functional status defined as 6MWT \> 25 m compared to Baseline * Improvement in quality-of-life defined as KCCQ score \> 10 compared to Baseline

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
    • Mitch Gheorghiu · Contactmitch.gheorghiu@cshs.org · 310-423-6152
    • Khaled Alsabaawi · Contactkhaled.alsabaawi@cshs.org · 310 423-6226
    • Hasan Al-Jilaihawi, MD · Sub investigator
    • Joanna Chikwe, MD · Sub investigator
    • Alfredo Trento, MD · Sub investigator
    • Dominic Emerson, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 36 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Jan 31, 2025
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2037
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06817148
Responsible party
Raj Makkar (MD, Cedars-Sinai Medical Center) — Principal investigator
First posted
Feb 10, 2025
Start date
Jan 31, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2037 (estimated)
Last update
Feb 10, 2025

Study contacts

Mitch Gheorghiu
Contact
mitch.gheorghiu@cshs.org
310 423-6152
Khaled Alsabaawi
Contact
khaled.alsabaawi@cshs.org
310 423-6226
Raj Makkar, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion